In this context, it was recently demonstrated that violacein reduces the production of CXCL12 and its interaction with CXCR4 in a model of human breast cancer through the inhibition of matrix metalloproteinase-2/9 activity [20]. The gene discussed is MMP2; the disease is breast carcinoma.